Journal of Antimicrobial Chemotherapy (1995) 35, 317-326
© 1995 The British Society for Antimicrobial Chemotherapy
research-article |
Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments
aDepartment of Thoracic Medicine, City Hospital Dudley Road, Birmingham, B 18 7QH, UK bDepartment of Microbiology, City Hospital Dudley Road, Birmingham, B 18 7QH, UK
Received 5 May 1994; accepted 19 September 1994
The efficacy of an antibiotic is usually predicted from serum concentration and MICs for likely pathogens, but in the lung, tissue concentrations may be more relevant. This study compares concentrations of a new fluoroquinolone, OPC-17116, in serum, epithelial lining fluid (ELF), alveolar macrophages and bronchial mucosa, in 24 adults. OPC-17116 400 mg was given daily for 4 days, and diagnostic bronchoscopy was performed up to 13 h after the final dose. Mucosal biopsies were taken from macroscopically normal sites, alveolar macrophages were harvested by lavage, and ELF volume was derived from urea concentrations in bronchial lavage fluid and blood. A microbiological assay, using Escherichia coli, was used to assay OPC-17116 concentration in serum, bronchial mucosa, ELF and alveolar macrophages. The mean concentration of OPC-17116 in serum was l·2mg/L. Serum concentrations were significantly exceeded in bronchial mucosa (mean ratio 3·13) in ELF (mean ratio 12·21) and in macrophages (mean ratio 194·52). Penetrations of these compartments considerably exceeded those reported for other fluoroquinolones, and concentrations in all tissues were substantially higher than previously reported MIC90 levels for a variety of bacteria, including Streptococcus pneumoniae. A clinical role for OPC-17116 is suggested in a wide range of respiratory infections, including those due to intracellular bacteria.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Kiem and J. J. Schentag Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining Fluid Antimicrob. Agents Chemother., January 1, 2008; 52(1): 24 - 36. [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Noreddin, V. L. Haynes, and G. G. Zhanel Pharmacokinetics and Pharmacodynamics of the New Quinolones Journal of Pharmacy Practice, December 1, 2005; 18(6): 432 - 443. [Abstract] [PDF]
|
|
|
|
|
|
A. A. Firsov, I. Y. Lubenko, S. N. Vostrov, Y. A. Portnoy, and S. H. Zinner Antistaphylococcal Effect Related to the Area under the Curve/MIC Ratio in an In Vitro Dynamic Model: Predicted Breakpoints versus Clinically Achievable Values for Seven Fluoroquinolones Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2642 - 2647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Niwa, Y. Kanamori, K. Hotta, H. Matsuno, O. Kozawa, S. Fujimoto, and T. Uematsu Priming by grepafloxacin on respiratory burst of human neutrophils: its possible mechanism J. Antimicrob. Chemother., October 1, 2002; 50(4): 469 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kanoh, J. Tamaoki, M. Kondo, Y. Nagano, and A. Nagai Effects of New Quinolones on Transepithelial Electrical Potential Difference of Tracheal Mucosa In Vivo Antimicrob. Agents Chemother., October 1, 2001; 45(10): 2928 - 2930. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Ono, Y. Ohmoto, K. Ono, Y. Sakata, and K. Murata Effect of grepafloxacin on cytokine production in vitro J. Antimicrob. Chemother., July 1, 2000; 46(1): 91 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Spangler, S. Bajaksouzian, M. R. Jacobs, and P. C. Appelbaum Postantibiotic Effects of Grepafloxacin Compared to Those of Five Other Agents against 12 Gram-Positive and -Negative Bacteria Antimicrob. Agents Chemother., January 1, 2000; 44(1): 186 - 189. [Abstract] [Full Text]
|
|
|
|
|
|
C. E. Langan, P. Zuck, F. Vogel, A. McIvor, W. Pierzchala, M. Smakal, H. Staley, and C. Marr Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis J. Antimicrob. Chemother., October 1, 1999; 44(4): 515 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. V. Piddock, M. Johnson, V. Ricci, and S. L. Hill Activities of New Fluoroquinolones against Fluoroquinolone-Resistant Pathogens of the Lower Respiratory Tract Antimicrob. Agents Chemother., November 1, 1998; 42(11): 2956 - 2960. [Abstract] [Full Text]
|
|
|
|
|
|
G. A. Pankuch, M. R. Jacobs, and P. C. Appelbaum Antipneumococcal Activity of Grepafloxacin Compared to That of Other Agents by Time-Kill Methodology Antimicrob. Agents Chemother., May 1, 1998; 42(5): 1263 - 1265. [Abstract] [Full Text]
|
|
|
|
|
|
S. Chodosh, S. Lakshminarayan, H. Swarz, and S. Breisch Efficacy and Safety of a 10-Day Course of 400 or 600 Milligrams of Grepafloxacin Once Daily for Treatment of Acute Bacterial Exacerbations of Chronic Bronchitis: Comparison with a 10-Day Course of 500 Milligrams of Ciprofloxacin Twice Daily Antimicrob. Agents Chemother., January 1, 1998; 42(1): 114 - 120. [Abstract] [Full Text]
|
|